Antihyperglycemic Effects of Short Term Resveratrol Supplementation in Type 2 Diabetic Patients

Abstract EN

The objective of this study was to examine the effectiveness of resveratrol in lowering blood glucose in the presence of standard antidiabetic treatment in patients with type 2 diabetes, in a randomized placebo-controlled double-blinded parallel clinical trial.

A total of 66 subjects with type 2 diabetes were enrolled in this study and randomly assigned to intervention group which was supplemented with resveratrol at a dose 1 g/day for 45 days and control group which received placebo tablets.

Body weight, blood pressure, fasting blood glucose, haemoglobin A1c, insulin, homeostatic assessments for insulin resistance, triglycerides, total cholesterol, low density lipoprotein, high density lipoprotein, and markers of liver and kidney damage were measured at baseline and after 45 days of resveratrol or placebo supplementation.

Resveratrol treatment significantly decreased systolic blood pressure, fasting blood glucose, haemoglobin A1c, insulin, and insulin resistance, while HDL was significantly increased, when compared to their baseline levels.

On the other hand, the placebo group had slightly increased fasting glucose and LDL when compared to their baseline levels.

Liver and kidney function markers were unchanged in the intervention group.

Overall, this study showed that resveratrol supplementation exerted strong antidiabetic effects in patients with type 2 diabetes.